Evidence map›Paper›PMID 24899624›Full record

ArticleBlood2014

Mitochondrial DNA copy number and future risk of B-cell lymphoma in a nested case-control study in the prospective EPIC cohort.

Fatemeh Saberi Hosnijeh, Qing Lan, Nathaniel Rothman, Chin San Liu, Wen-Ling Cheng, Alexandra Nieters, Per Guldberg, Anne Tjønneland, Daniele Campa, Alessandro Martino and 29 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 14 countries.

Fatemeh Saberi HosnijehInstitute for Risk Assessment Sciences, Division Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands; Zanjan University of Medical Sciences, Zanjan, Iran;
Qing LanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD;
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD;
Chin San LiuDepartment of Neurology and Vascular and Genomic Center, Changhua Christian Hospital, Changhua, Taiwan; Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan;
Wen-Ling ChengLaboratory of Mitochondrial Medicine, Chunghua Christian Hospital, Taipei, Taiwan;
Alexandra NietersCentre of Chronic Immunodeficiency, University Medical Centre Freiburg, Freiburg, Germany;
Per GuldbergDanish Cancer Society Research Center, Copenhagen, Denmark;
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen, Denmark;
Daniele CampaGenomic Epidemiology Group, German Cancer Research Center, Heidelberg, Germany;
Alessandro MartinoGenomic Epidemiology Group, German Cancer Research Center, Heidelberg, Germany;
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Nuthetal, Germany;
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece; WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece;
Pagona LagiouWHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece; Department of Epidemiology, Harvard School of Public Health, Boston, MA; Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece;
Dimitrios TrichopoulosHellenic Health Foundation, Athens, Greece; Department of Epidemiology, Harvard School of Public Health, Boston, MA; Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece;
Vittorio KroghEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
Rosario TuminoCancer Registry and Histopathology Unit, "Civic - M.P. Arezzo" Hospital, ASP Ragusa, Italy;
Salvatore PanicoDepartment of Clinical Medicine and Surgery, Federico II University, Naples, Italy;
Giovanna MasalaMolecular and Nutritional Epidemiology Unit, ISPO Cancer Research and Prevention Institute, Florence, Italy;
Elisabete WeiderpassDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway; Department of Research, Cancer Registry of Norway, Oslo, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Samfundet Folkhälsan, Helsinki, Finland;
José María Huerta CastañoDepartment of Epidemiology, Murcia Regional Health Council, Murcia, Spain; CIBER Epidemiology and Public Health CIBERESP, Spain;
Eva ArdanazCIBER Epidemiology and Public Health CIBERESP, Spain; Navarre Public Health Institute, Pamplona, Spain;
Núria SalaTranslational Research Laboratory and Unit of Nutrition, Environment and Cancer Research Program in Cancer Epidemiology, Catalan Institute of Oncology, Biomedical Research Institute (IDIBELL), Barcelona, Spain;
Miren DorronsoroPublic Health Direction and Biodonostia Research Institute Ciberesp, Basque Regional Health Department, Vitoria, Spain;
J Ramón QuirósPublic Health Directorate, Asturias, Spain;
María-José SánchezCIBER Epidemiology and Public Health CIBERESP, Spain; Andalusian School of Public Health, Granada, Spain; Instituto de Investigación Biosanitario de Granada, Granada, Spain;
Beatrice MelinDepartment of Radiation Sciences, Oncology Umeå University, Umeå, Sweden;
Ann Sofie JohanssonDepartment of Radiation Sciences, Oncology Umeå University, Umeå, Sweden;
Johan MalmDepartment of Laboratory Medicine, Clinical Chemistry, Lund University, Malmö, Sweden; Skåne University Hospital, Malmö, Sweden;
Signe BorgquistDivision of Oncology, Department of Clinical Sciences, Lund University, Malmö, Sweden;
Petra H PeetersDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht;
H Bas Bueno-de-MesquitaNational Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands; The School of Public Health, Imperial College London, London, United Kingdom;
Nick WarehamMRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom; School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom;
Kay-Tee KhawSchool of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom;
Ruth C TravisCancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom;
Paul BrennanGenetics Section, International Agency for Research on Cancer, Lyon, France;
Afshan SiddiqDepartment of Genomics of Common Disease, School of Public Health, Imperial College London, London, United Kingdom;
Elio RiboliDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom; and.
Paolo VineisThe School of Public Health, Imperial College London, London, United Kingdom; Human Genetics Foundation, Turin, Italy.
Roel VermeulenInstitute for Risk Assessment Sciences, Division Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht;
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESImperial College London · GBDanish Cancer Society · DKHeidelberg University · DELund University · SEUmeå University · SEUniversity Medical Center Utrecht · NLUtrecht University · NLAcademy of Athens · GRAddenbrooke's Hospital · GBAzienda Usl 8 Arezzo · ITBiogipuzkoa Health Research Institute · ESCentre International de Recherche sur le Cancer · FRChanghua Christian Hospital · TWChina Medical University · TWDivision of Cancer Epidemiology and GeneticsFederico II University Hospital · ITFolkhälsans Forskningscentrum · FIFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Institute of Human Nutrition · DE

Funding

Cancer Research UK 14136Cancer Research UK 16491Medical Research Council G0401527Medical Research Council G1000143World Health Organization 001
6 · The paper itself

Abstract

It has been suggested that mitochondrial dysfunction and DNA damage are involved in lymphomagenesis. Increased copy number of mitochondrial DNA (mtDNA) as a compensatory mechanism of mitochondrial dysfunction previously has been associated with B-cell lymphomas, in particular chronic lymphocytic leukemia (CLL). However, current evidence is limited and based on a relatively small number of cases. Using a nested case-control study, we extended these findings with a focus on subtype-specific analyses. Relative mtDNA copy number was measured in the buffy coat of prospectively collected blood of 469 lymphoma cases and 469 matched controls. The association between mtDNA copy number and the risk of developing lymphoma and histologic subtypes was examined using logistic regression models. We found no overall association between mtDNA and risk of lymphoma. Subtype analyses revealed significant increased risks of CLL (n = 102) with increasing mtDNA copy number (odds ratio = 1.34, 1.44, and 1.80 for quartiles 2-4, respectively; P trend = .001). mtDNA copy number was not associated with follow-up time, suggesting that this observation is not strongly influenced by indolent disease status. This study substantially strengthens the evidence that mtDNA copy number is related to risk of CLL and supports the importance of mitochondrial dysfunction as a possible mechanistic pathway in CLL ontogenesis.

Indexed as

AdultAgedCase-Control StudiesDNA Copy Number VariationsDNA, MitochondrialFemaleFollow-Up StudiesHodgkin DiseaseHumansLymphoma, B-CellLymphoma, T-CellMaleMiddle AgedMitochondriaPrognosisProspective StudiesDNA, Mitochondrial

Identifiers

PMID24899624
PMCPMC4110659
OpenAlexW1978023691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.